Treatment patterns and outcomes by mismatch repair/microsatellite instability status among patients with primary advanced or recurrent endometrial cancer in the United States
Platinum-based chemotherapy combinations, the recommended first-line treatment, were not used in ≈ 40% of patients. TTNT rates were similar to the PFS rates in the carboplatin-paclitaxel arms in the RUBY and GY-018 trials; OS rates were similar to RUBY, highlighting the potential for combination therapies to improve outcomes.
Authors
- Solomon J. Lubinga (ORCID: https://orcid.org/0000-0003-0539-9156)
- Dana M. Chase (ORCID: https://orcid.org/0000-0002-1073-8688)
- Monica Kobayashi
- John Chan (ORCID: https://orcid.org/0000-0002-4422-081X)
- Pratyk Gomez
Institutions
- UCLA Health (US)
- California Pacific Medical Center (US)
- GlaxoSmithKline (India) (IN)
- GlaxoSmithKline (United States) (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1080/14796694.2025.2516891
- Citations
- 3
- Primary Topic
- Genetic factors in colorectal cancer
- Type
- article
- Field-Weighted Citation Impact
- 4.41
Funders
- GlaxoSmithKline